Comparative Pharmacology
Head-to-head clinical analysis: ALA CORT versus DERMATOP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA CORT versus DERMATOP.
ALA-CORT vs DERMATOP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Prednicarbate is a corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid from membrane phospholipids.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
Apply a thin layer to affected skin areas twice daily (morning and evening) for up to 4 weeks. Do not use more than 50 g per week.
None Documented
None Documented
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Terminal elimination half-life: approximately 100 hours (range 68-120 hours) following topical administration; prolonged accumulation with chronic use due to high lipophilicity and slow release from skin depot.
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Primarily hepatic metabolism with inactive metabolites; <10% excreted renally as unchanged drug; minimal biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid